ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO168

Patients with Focal Segmental Glomerulosclerosis (FSGS): A Claims Analysis of Clinical and Economic Outcomes

Session Information

Category: Glomerular

  • 1005 Clinical Glomerular Disorders

Authors

  • Nazareth, Tara A, Mallinckrodt Pharmaceuticals, Hampton, New Jersey, United States
  • Kariburyo, Furaha, STATinMED Research, Ann Arbor, Michigan, United States
  • Kirkemo, Aaron, Mallinckrodt Pharmaceuticals, Hampton, New Jersey, United States
  • Xie, Lin, STATinMED Research, Ann Arbor, Michigan, United States
  • Pavlova-Wolf, Anna, Mallinckrodt, Henderson, Texas, United States
  • Bartels-Peculis, Laura, Mallinckrodt Pharmaceuticals, Hampton, New Jersey, United States
  • Vaidya, Neel, STATinMED Research, Ann Arbor, Michigan, United States
  • Sim, John J., None, Los Angeles, California, United States
Background

FSGS is the leading cause of idiopathic nephrotic syndrome (NS) in the US, accounting for 35% of cases (Haas et al., 1997; Kitiyakara et al., 2004). Given the complexity of diagnosis and treatment, many patients with FSGS have renal insufficiency at clinical presentation. Within 10 years, >50% develop kidney failure; post-transplant, FSGS can recur in 30-40% of patients (MedlinePlus FSGS; NephCure FSGS fact sheet). We studied a prevalent cohort to quantify the burden of illness with FSGS.

Methods

Commercially-insured patients ≥18 years with ≥2 diagnoses of FSGS [Diagnosis (Dx) code ICD-9=582.1 or ICD-10: N031, N033, N020, N040] were identified from Truven Marketscan® US healthcare claims data during 1/1/12-12/31/15; the first Dx date was denoted the index date. Patients with claims for secondary causes of NS (Dx) were excluded. During 1 year follow-up, demographics and clinical characteristics, clinical health outcomes, and all-cause healthcare resource utilization [HCRU: emergency room (ER), inpatient (IP), outpatient (OP), and medications (Rx)] were assessed using diagnosis, procedure and drug codes. Costs attributable to HCRU were evaluated in all patients enrolled in fee-for-service plans (FFS), as well as in the top 5% specifically.

Results

1,187 patients were identified [59.0% male, mean age=45.1 years, with hematuria (17.7%), mean Charlson Comorbidity Index score=2.5, from South and North Central US (62.3%)]. 14.7% of patients had urinary tract infections, 4.6% pneumonia and 2.7% septicemia. 12.5% were placed on dialysis and 4.1% received a renal transplant. 29.0% of patients used the ER and 20.6% had IP stays. 21.9 mean Rx were dispensed. Among FFS patients (n=949), total and mean (SD) costs were $42.1 million and $44,397 ($102,481.8), respectively. 5% of patients (n=47) were responsible for 44.4% of total costs equaling $18.7 million, for a mean (SD) per patient cost of $397,973.8 ($219,457.3); OP, IP, Rx and ER represented 57.2%, 30.5%, 11.8%, and 0.5% of total costs, respectively.

Conclusion

Our study characterizes the 1-year burden of illness with FSGS and identifies a small group of patients incurring high cost, mostly via IP and OP use. Understanding this subset and their unmet needs, as well as their longer-term outcomes and costs, is a priority.

Funding

  • Commercial Support –